Jul 25, 2018
The FDA has approved AbbVie's Gonadotropin-Releasing Hormone (GnRH) antagonist Elagolix on Tuesday. FDA has given green light to the first oral treatment for endometriosis pain. The drug is branded as Orilissa, and is expected to be available in U.S. pharmacies in August. It will carry a list price of about $850 per...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper